Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study

Acute myeloid leukemia (AML) with FLT3-mutation carries a poor prognosis, and allogeneic stem cell transplantation (allo-SCT) is recommended at first complete remission (CR1). We assessed 462 adults (median age 50 years) with FLT3-mutated AML allografted between 2010 and 2015 from a matched related...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Ali Bazarbachi, Myriam Labopin, Giorgia Battipaglia, Azedine Djabali, Edouard Forcade, William Arcese, Gerard Socié, Didier Blaise, Joerg Halter, Sabine Gerull, Jan J. Cornelissen, Patrice Chevallier, Johan Maertens, Nicolaas Schaap, Jean El-Cheikh, Jordi Esteve, Arnon Nagler, Mohamad Mohty
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	SAABRON PRESS 2019-03-01
Rangatū:	Clinical Hematology International
Ngā marau:	Allogeneic stem cell transplantation Acute myeloid leukemia FLT3 mutation In vivo T-cell depletion Sorafenib
Urunga tuihono:	https://www.atlantis-press.com/article/125905879/view
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!